Longboard Pharmaceuticals... (LBPH)
Longboard Pharmaceuticals Statistics
Share Statistics
Longboard Pharmaceuticals has 39.05M shares outstanding. The number of shares has increased by 0.43% in one year.
| Shares Outstanding | 39.05M |
| Shares Change (YoY) | 0.43% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 24.97M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 1.59M, so 4.07% of the outstanding shares have been sold short.
| Short Interest | 1.59M |
| Short % of Shares Out | 4.07% |
| Short % of Float | 5.38% |
| Short Ratio (days to cover) | 1.93 |
Valuation Ratios
The PE ratio is -2.52 and the forward PE ratio is null. Longboard Pharmaceuticals's PEG ratio is 0.53.
| PE Ratio | -2.52 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 3.35 |
| P/FCF Ratio | -2.69 |
| PEG Ratio | 0.53 |
Enterprise Valuation
Longboard Pharmaceuticals has an Enterprise Value (EV) of 123.18M.
| EV / Sales | 0 |
| EV / EBITDA | -2.17 |
| EV / EBIT | -2.42 |
| EV / FCF | -2.42 |
Financial Position
The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.
| Current Ratio | 5.14 |
| Quick Ratio | 5.14 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -132.99% and Return on Invested Capital is -138.7%.
| Return on Equity | -132.99% |
| Return on Assets | -107.35% |
| Return on Invested Capital | -138.7% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.09M |
| Employee Count | 50 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.09, so Longboard Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 56.75 |
| 200-Day Moving Average | 33.99 |
| Relative Strength Index (RSI) | 79.7 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -5K |
| Operating Income | -56.76M |
| Net Income | -54.42M |
| EBITDA | -56.75M |
| EBIT | -56.76M |
| Earnings Per Share (EPS) | -2.39 |
Balance Sheet
The company has 14.33M in cash and 475K in debt, giving a net cash position of 13.86M.
| Cash & Cash Equivalents | 14.33M |
| Total Debt | 475K |
| Net Cash | 13.86M |
| Retained Earnings | -140.56M |
| Total Assets | 297M |
| Working Capital | 274.68M |
Cash Flow
In the last 12 months, operating cash flow was -50.87M and capital expenditures 0, giving a free cash flow of -50.87M.
| Operating Cash Flow | -50.87M |
| Capital Expenditures | 0 |
| Free Cash Flow | -50.87M |
| FCF Per Share | -2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -39.71% |
| FCF Yield | -37.12% |
Analyst Forecast
Currently there are no analyst rating for LBPH.
| Price Target | $60 |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 63.59 |
| Piotroski F-Score | 3 |